CA2390839A1 - Facteur alpha hiii de transformation cellulaire - Google Patents

Facteur alpha hiii de transformation cellulaire Download PDF

Info

Publication number
CA2390839A1
CA2390839A1 CA002390839A CA2390839A CA2390839A1 CA 2390839 A1 CA2390839 A1 CA 2390839A1 CA 002390839 A CA002390839 A CA 002390839A CA 2390839 A CA2390839 A CA 2390839A CA 2390839 A1 CA2390839 A1 CA 2390839A1
Authority
CA
Canada
Prior art keywords
polypeptide
replaced
seq
sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002390839A
Other languages
English (en)
Inventor
Ying-Fei Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2390839A1 publication Critical patent/CA2390839A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne une nouvelle protéine humaine appelée TGF (Transforming Growth Factor) Alpha III, ainsi que des polynucléotides isolés codant pour cette protéine. L'invention concerne également des vecteurs, des cellules hôtes, des anticorps et des techniques de recombinaison permettant de produire cette protéine humaine. L'invention concerne enfin des techniques de diagnostique et des thérapies utiles dans le diagnostic et le traitement des troubles liés à cette nouvelle protéine humaine.
CA002390839A 1999-12-02 2000-12-01 Facteur alpha hiii de transformation cellulaire Abandoned CA2390839A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16838799P 1999-12-02 1999-12-02
US60/168,387 1999-12-02
PCT/US2000/032745 WO2001040251A1 (fr) 1999-12-02 2000-12-01 Facteur alpha hiii de transformation cellulaire

Publications (1)

Publication Number Publication Date
CA2390839A1 true CA2390839A1 (fr) 2001-06-07

Family

ID=22611307

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002390839A Abandoned CA2390839A1 (fr) 1999-12-02 2000-12-01 Facteur alpha hiii de transformation cellulaire

Country Status (5)

Country Link
EP (1) EP1244686A4 (fr)
JP (1) JP2003515326A (fr)
AU (1) AU2056801A (fr)
CA (1) CA2390839A1 (fr)
WO (1) WO2001040251A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3639860A1 (fr) * 2013-09-03 2020-04-22 Mayo Foundation for Medical Education and Research Réduction du risque de problèmes cardiaques majeurs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0873360A4 (fr) * 1996-01-04 2000-06-21 Human Genome Sciences Inc Facteur transformant de croissance alpha hiii
EP1021532A2 (fr) * 1997-10-08 2000-07-26 Sagami Chemical Research Center Proteines humaines comportant des domaines transmembranaires et adn codant ces proteines

Also Published As

Publication number Publication date
AU2056801A (en) 2001-06-12
EP1244686A1 (fr) 2002-10-02
WO2001040251A1 (fr) 2001-06-07
EP1244686A4 (fr) 2003-04-23
JP2003515326A (ja) 2003-05-07

Similar Documents

Publication Publication Date Title
US6593112B1 (en) Polynucleotides encoding fibroblast growth factor 15
US6953667B2 (en) Antibodies against human protein HUVDJ43
US20060039905A1 (en) Galectin 11
US20080146505A1 (en) 47 Human Secreted Proteins
US20060079670A1 (en) 98 human secreted proteins
US20050221376A1 (en) Metalloproteinase ADAM 22
US20060036089A1 (en) 33 human secreted proteins
US6605441B1 (en) Antibodies against fibroblast growth factor 11
US20050064458A1 (en) 143 human secreted proteins
WO2001012781A1 (fr) 13 proteines associees au cancer du colon et au colon humain
US20070190612A1 (en) 31 Human Secreted Proteins
US20050019824A1 (en) Fibroblast Growth Factor-10
EP1203018A1 (fr) Prostate humaine 26 et cancer de la prostate associe aux proteines
EP1192168A1 (fr) Galectine 11
US20020025553A1 (en) Transforming growth factor alpha HIII
AU7354700A (en) Human neuropeptide receptor
WO2000071152A1 (fr) Facteur 10 de croissance des fibroblastes
US20050026838A1 (en) Fibroblast Growth Factor-13
US20030175778A1 (en) Interferon Receptor HKAEF92
WO2001053343A1 (fr) Polynucleotides, polypeptides et anticorps humains
WO2000067775A1 (fr) Facteur de croissance des fibroblastes (fgf) 15
WO2001007608A1 (fr) Interferon derive du keratinocyte
WO2000071715A1 (fr) Facteur 11 de croissance des fibroblastes
WO2000071582A1 (fr) Facteur 14 de croissance du fibroblaste
CA2390839A1 (fr) Facteur alpha hiii de transformation cellulaire

Legal Events

Date Code Title Description
FZDE Dead